Search

Diphemanil

CZEN 002

It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. … The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane.

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer.

Leptin

Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. … Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite

Nigericin

A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)

Jojoba oil

Jojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Scutellaria lateriflora

Scutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Forasartan

As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.

Sutilain

[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]

Adrafinil

It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. … Adrafinil does not currently have FDA approval and is thus unregulated in the United States.